Andrew Bomback, MD
Nephrology · New York, NYNPI 1013129816
Payments from drug & device makers
Across 155 payments — averaging $21,782 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2.9M
- Genentech, Inc.$200K
- Apellis Pharmaceuticals, Inc.$187K
- Travere Therapeutics, Inc.$24K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$22K
- Amgen$16K
- plus $40K from 12 others
Across 8 payments — averaging $4818.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$37K
- F. Hoffmann-la Roche AG$1K
- Novartis Pharma AG$485
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $2,887,374 |
| Genentech, Inc. | 22 | $199,574 |
| Apellis Pharmaceuticals, Inc. | 19 | $186,749 |
| Travere Therapeutics, Inc. | 32 | $23,720 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $22,202 |
| Amgen(2 entities) | 9 | $16,330 |
| Aurinia Pharma U.S., Inc. | 10 | $11,895 |
| GSK | 5 | $10,750 |
| AstraZeneca | 3 | $6,132 |
| ANI Pharmaceuticals, Inc. | 3 | $3,575 |
| Novartis Pharma AG | 1 | $2,925 |
| Otsuka Pharmaceutical Co., Ltd. | 4 | $2,000 |
| Roche Products Limited | 1 | $1,763 |
| Novo Nordisk AS | 1 | $880 |
| Mallinckrodt Hospital Products Inc. | 1 | $146 |
| Otsuka America Pharmaceutical, Inc. | 2 | $122 |
| Vifor Pharma, Inc. | 1 | $82 |
| Sanofi | 2 | $54 |
How this compares
$3,376,272 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in New York
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Pietro CanettaNew York$3.2M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Kirk CampbellNew York$1.1M
- Jai RadhakrishnanNew York$995K
- Girish NadkarniNew York$978K
- David GoldfarbNew York$808K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.